SCII

SC II Acquisition Corp.
5 filings tracked
financialsasset managementSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

SC II Acquisition Corp. is demonstrating a disciplined approach to capital preservation, transforming its trust account into a high-yield vehicle for shareholders. As of March 31, 2026, the trust has grown to $174.6 million, pushing the redemption value to $10.12 per share.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The perceived stability of SC II Acquisition Corp. may be a mirage, as its reported net income of $1.6 million is entirely derived from interest on trust assets rather than any productive business operation.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every SCII filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a classic SPAC tension between short-term yield and long-term execution risk. On one hand, the company has successfully leveraged the high-interest-rate environment to increase the trust's value, providing a tangible return for patient shareholders. On the other hand, the total absence of operating revenue and the reliance on non-binding sponsor loans highlight the fragility of the entity as a standalone business. Ultimately, the investment thesis hinges on management's ability to identify and close a target before the redemption window or the Nasdaq deadline expires. While the current balance sheet is healthy in terms of raw cash, the transition from a 'yield-plus' shell to a functioning public company remains the primary hurdle. Investors are essentially trading a guaranteed, modest interest return for a call option on an undisclosed future acquisition.

Selected Quarter

Core Takeaway

The company is effectively a high-yield cash vehicle currently, but its long-term value depends entirely on a successful merger before the 2027/2028 deadlines.

Investor Lens

The trade-off is between the current 1.2% premium over IPO price and the risk of total liquidity loss via delisting.

Watch Next

Announcement of a definitive merger agreement or any extension requests for the Combination Period.

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.03Q1 '26 (10-K)-0.08Q2 '26 (10-Q)+0.27Q2 '26 (10-Q)

Signal Timeline

6 of 17
Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 15

Generated $1.6M net income in Q1 driven by trust interest.

earnings beat
70%
bullishMay 15

Low G&A burn relative to high interest income from trust assets.

margin expansion
60%
bearishMay 15

Strict Nasdaq 36-month requirement creates potential delisting risk.

regulatory action
50%
bullishMay 15

Generated $1.6M net income in Q1 driven by trust interest.

earnings beat
70%
bullishMay 15

Low G&A burn relative to high interest income from trust assets.

margin expansion
60%
bearishMay 15

Strict Nasdaq 36-month requirement creates potential delisting risk.

regulatory action
50%

Filing History

10-QMay 15, 2026
Expand Sequence

The Q1 2026 filing reveals a classic SPAC tension between short-term yield and long-term execution risk. On one hand, the company has successfully leveraged the high-interest-rate environment to increase the trust's value, providing a tangible return for patient shareholders. On the other hand, the total absence of operating revenue and the reliance on non-binding sponsor loans highlight the fragility of the entity as a standalone business. Ultimately, the investment thesis hinges on management's ability to identify and close a target before the redemption window or the Nasdaq deadline expires. While the current balance sheet is healthy in terms of raw cash, the transition from a 'yield-plus' shell to a functioning public company remains the primary hurdle. Investors are essentially trading a guaranteed, modest interest return for a call option on an undisclosed future acquisition.

10-QMay 13, 2026
Expand Sequence

The Q1 2026 filing presents a dichotomy between aggressive growth and structural fragility. On one hand, the fund is successfully deploying capital into high-yield opportunities and delivering strong nominal distributions. On the other, the underlying cash flow is not yet self-sustaining, leaving the vehicle dependent on external financing and management's willingness to waive fees. The ultimate trajectory for investors depends on whether the portfolio's scaling can outpace the rising cost of leverage and the potential for credit losses. While the floating-rate nature of the assets is a strength, the narrowing margin between net investment income and distributions suggests there is very little room for error in the current credit environment.

10-KMar 31, 2026
Expand Sequence

The 10-K filing reveals a classic SPAC trade-off between a well-funded acquisition platform and the inherent risks of structural dilution and management conflict. SC II has successfully raised significant capital and established a clear operational mandate, but it remains a speculative bet on the team's ability to identify a high-quality target in a competitive environment. The current financial position is stable, with a redemption price of approximately $10.02 per share providing a floor for investors. Ultimately, the impact of this filing underscores the urgency of the combination window. Investors must weigh the potential for management's operational expertise to drive value against the reality of a governance structure that heavily favors the sponsor. The success of the vehicle will depend on whether the team can leverage its defense-sector network to find a target that outweighs the structural headwinds of the SPAC model.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.